Weimin Wang

CEO at Sanegene Bio

Speaker

Dr. Weimin Wang is one of the industry's leading oligonucleotide chemists with nearly 30 years of research experience in the field. Dr. Wang has been a key contributor to the RNA therapeutic industry for over 20 years, with more than 60 scientific publications and patents related to RNAi therapeutics. Before founding SanegeneBio, he served as the Executive Director of Chemistry at Dicerna Pharmaceuticals (acquired by Novo Nordisk in 2021) where his team played a crucial role in developing Dicerna's liver-targeting GalXC technology, along with extrahepatic delivery platforms. Prior to joining Dicerna, Dr. Wang was part of Merck & Co. through its acquisition of Sirna, where he developed one of the first lipid nanoparticle delivery systems for nucleic acid therapeutics. Throughout his tenure at Sirna, Merck, and Dicerna, Dr. Wang demonstrated his extensive expertise by evaluating numerous external opportunities for nucleic acid drug discovery and delivery technology, as well as managing numerous significant partnership collaborations.